Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) announced that on February 28, 2026 its Compensation Committee granted inducement stock options to one new employee to purchase 20,000 shares at an exercise price of $5.25 per share under the company's 2025 Inducement Plan.

Vesting: 25% after one year of service, then the remaining 75% vesting in 36 equal monthly installments, all subject to continued employment. The Plan was adopted on December 24, 2025 and the awards comply with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – CADL

-3.91%

1 alert

-3.91% News Effect

On the day this news was published, CADL declined 3.91%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 20,000 shares Exercise price: $5.25 per share Initial vesting tranche: 25% +5 more

8 metrics

Inducement options 20,000 shares Stock options granted to one new employee

Exercise price $5.25 per share Strike price for inducement stock options

Initial vesting tranche 25% Vests on first anniversary of employee’s start date

Remaining vesting 75% over 36 months Vests in 36 equal monthly installments after first anniversary

Plan adoption date December 24, 2025 Board adoption date of 2025 Inducement Plan

Nasdaq rule Rule 5635(c)(4) Basis for inducement equity grants outside shareholder-approved plan

Current price $5.25 Price at prior close before this news

52-week range $4.25 – $9.13 Low and high prior to this announcement

Market Reality Check

Price: $4.66 Vol: Volume 2,088,337 is 59% a...

high vol

$4.66 Last Close

Volume Volume 2,088,337 is 59% above the 20-day average of 1,310,393, indicating elevated trading ahead of this HR-focused news. high

Technical Shares at $5.25 are trading below the 200-day MA of $5.57 and well under the $9.13 52-week high.

Peers on Argus

CADL gained 1.94% with higher volume. Peers were mixed: ANNX (+5.46%), VNDA (+4....

CADL gained 1.94% with higher volume. Peers were mixed: ANNX (+5.46%), VNDA (+4.7%), MNPR (+1.53%), CAPR (+0.61%), while TNXP declined (-1.62%), suggesting stock-specific factors rather than a unified sector move.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Conference presentation	Neutral	+2.4%	TD Cowen health care conference presentation and webcast availability details.
Feb 19	Equity offering priced	Negative	-14.2%	Pricing of 18,348,624-share public offering at $5.45 expected to raise $100M.
Feb 19	Equity offering proposed	Negative	-14.2%	Proposed $100M common stock offering under effective shelf registration.
Feb 19	Royalty funding deal	Positive	-14.2%	$100M royalty funding agreement with RTW tied to CAN-2409 launch in prostate cancer.
Feb 11	Conference participation	Neutral	-4.0%	Glioblastoma summit presentations on HSV platform and CAN-3110 program.

Pattern Detected

Recent financing and royalty news around CAN-2409 drew sharp negative reactions, while conference updates produced modest moves, showing sensitivity to capital-raising headlines.

Recent Company History

Over the past weeks, CADL issued multiple financing and partnership updates tied to CAN-2409 and its pipeline. A proposed and then priced offering around $100 million coincided with -14.2% moves, while a $100 million royalty funding agreement with RTW shared that reaction despite being strategically supportive. In contrast, conference presentation announcements on Feb 11 and Feb 24 triggered relatively modest price changes, highlighting a pattern where capital structure news dominates trading behavior.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-08-14

$300,000,000 registered capacity

An active Form S-3 shelf dated Aug 14, 2025 allows CADL to offer up to $300,000,000 of securities, including up to $50,000,000 of common stock via an at-the-market agreement with Jefferies LLC. The shelf has been used at least 2 times via recent 424B5 offerings and remains effective through Aug 14, 2028.

Market Pulse Summary

This announcement details a standard inducement stock option grant of 20,000 shares at $5.25 under t...

Analysis

This announcement details a standard inducement stock option grant of 20,000 shares at $5.25 under the 2025 Inducement Plan, structured with time-based vesting tied to continued service. Contextually, it follows a period of significant capital activity, including large equity offerings and a royalty funding deal for CAN-2409. Investors tracking dilution and incentives may watch future equity grants and updates on the company’s shelf and clinical milestones.

Key Terms

stock options, nasdaq listing rule 5635(c)(4)

2 terms

stock options financial

"granted to one new employee, stock options to purchase an aggregate of 20,000 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 20,000 shares of the Company’s common stock, with a per share exercise price of $5.25.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of the employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 36 equal monthly installments thereafter. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

FAQ

What inducement awards did Candel Therapeutics (CADL) grant on February 28, 2026?

Candel granted inducement stock options to a new employee to buy 20,000 shares at $5.25 per share. According to the company, the awards were made under the 2025 Inducement Plan as material inducements under Nasdaq Listing Rule 5635(c)(4).

How do the Candel (CADL) inducement options vest and when does vesting start?

Vesting begins with 25% after the first anniversary of employment, then monthly over 36 months for the remaining 75%. According to the company, all vesting is conditioned on the employee's continued service through each vesting date.

What is the exercise price and plan governing the CADL inducement options?

The exercise price is $5.25 per share, and the awards were granted under the company's 2025 Inducement Plan. According to the company, the Plan was adopted by the board on December 24, 2025.

Why did Candel Therapeutics (CADL) issue inducement awards under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as material inducements to recruit a new employee and comply with Nasdaq Listing Rule 5635(c)(4). According to the company, the grants were tied to the employee entering into employment with Candel.

Will the Candel (CADL) inducement options dilute existing shareholders and when might dilution occur?

The awards cover 20,000 shares, which could dilute shareholders if exercised; timing depends on exercise and vesting. According to the company, the options are subject to vesting and the exercise price of $5.25 per share.